Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLDX 
Celldex Therapeutics Inc (CLDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CLDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $56.25
1 Year Target Price $56.25
| 10 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.23% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.62B USD | Price to earnings Ratio - | 1Y Target Price 56.25 |
Price to earnings Ratio - | 1Y Target Price 56.25 | ||
Volume (30-day avg) 14 | Beta 1.19 | 52 Weeks Range 14.40 - 47.00 | Updated Date 09/14/2025 |
52 Weeks Range 14.40 - 47.00 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8747.53% |
Management Effectiveness
Return on Assets (TTM) -19.08% | Return on Equity (TTM) -27.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 996334000 | Price to Sales(TTM) 280.42 |
Enterprise Value 996334000 | Price to Sales(TTM) 280.42 | ||
Enterprise Value to Revenue 172.08 | Enterprise Value to EBITDA -17.34 | Shares Outstanding 66406500 | Shares Floating 53206915 |
Shares Outstanding 66406500 | Shares Floating 53206915 | ||
Percent Insiders 0.19 | Percent Institutions 111.33 |
Upturn AI SWOT
Celldex Therapeutics Inc
Company Overview
History and Background
Celldex Therapeutics, Inc. was founded in 1991. It is a biopharmaceutical company dedicated to developing and commercializing new treatments for cancer and other difficult-to-treat diseases. Initially focused on monoclonal antibodies, Celldex has evolved to focus on antibody-drug conjugates (ADCs) and other innovative therapies.
Core Business Areas
- Antibody-Drug Conjugates (ADCs): Celldex develops ADCs that target specific cancer cells, delivering cytotoxic payloads directly to tumors. This includes developing and testing clinical trials with various ADC therapies.
- Antibody-Based Therapies: Celldex continues to research and develop novel antibody-based therapies to enhance the immune response against cancer.
Leadership and Structure
Anthony Marucci serves as President and CEO. The company has a typical organizational structure for a biotechnology company, with departments for research and development, clinical operations, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Varlilumab: Varlilumab is a CD27 agonist antibody in development as a monotherapy and in combination with other therapies for various cancer types. Being a clinical asset, there is no current market share or revenue generation. Competitors include companies developing other immunotherapies such as Merck (Keytruda), Bristol Myers Squibb (Opdivo), and Roche (Tecentriq).
- CDX-0159: CDX-0159 is an anti-KIT monoclonal antibody in clinical development for chronic urticaria. Being a clinical asset, there is no current market share or revenue generation. Competitors include Novartis (Xolair) and other companies developing treatments for urticaria.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory oversight. There is a growing demand for targeted therapies and immunotherapies, especially in oncology.
Positioning
Celldex is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other diseases. Its competitive advantage lies in its expertise in antibody engineering and ADC technology.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be in the hundreds of billions of dollars. Celldex is positioned to capture a portion of this TAM with its targeted therapies, assuming successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary antibody and ADC technology platforms
- Experienced management team
- Strong intellectual property portfolio
- Pipeline of clinical-stage assets
- Focus on targeted therapies
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- Risk of regulatory setbacks
- Lack of commercialized products currently
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal R&D and acquisitions
- Successful clinical trial results leading to regulatory approvals
- Increasing demand for targeted therapies and immunotherapies
- Advancements in antibody engineering and ADC technology
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
Competitive Landscape
Celldex faces significant competition from larger pharmaceutical companies with greater resources. Celldex's success depends on its ability to develop and commercialize innovative therapies that address unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by preclinical and clinical development progress, along with strategic partnerships.
Future Projections: Future growth is highly dependent on clinical trial success and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for Varlilumab and CDX-0159, expanding research and development efforts, and exploring potential partnerships.
Summary
Celldex is a clinical-stage biotech company with promising antibody and ADC technologies, but it faces significant risks due to its reliance on clinical trial outcomes and intense competition. Their financial position is dependent on successful partnerships and fundraising. The company needs to achieve clinical milestones to increase its value and attract investment. Regulatory hurdles and competitive pressures are significant factors to consider.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Company website
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share values are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celldex Therapeutics Inc
Exchange NASDAQ | Headquaters Hampton, NJ, United States | ||
IPO Launch date 2008-03-10 | Founder, President, CEO & Director Mr. Anthony S. Marucci M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 186 | Website https://www.celldex.com |
Full time employees 186 | Website https://www.celldex.com | ||
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.